Summary
The purpose of this study is to determine whether CP-547,632, an oral VEGFR-2 tyrosine kinase inhibitor is effective in the treatment of epithelial ovarian cancer, primary peritoneal serous cancer, or fallopian tube cancer for patients who have failed first line platinum-based therapy and have a persistent rising CA-125.
Key Facts
Lead Sponsor
Enrollment
Start Date
Study Type
Official Title
Interventions
Conditions
Eligibility
Age Range
Sex
Inclusion Criteria: * Histologically proven epithelial ovarian cancer, primary peritoneal serous cancer, or fallopian tube cancerRecurrent or persistent elevated CA-125. * For the purpose of this study, elevated CA-125 is defined as a value of ≥40 U/ml on two separate consecutive determinations made ≥1 week apart. * CA-125 values obtained within 4 weeks of abdominal surgery should not be taken into account. * No definitive disease or clinical and findings of small volume disease (\£1cm by spiral CT or \£2cm by conventional CT or clinical exam). Exclusion Criteria: * No prior exposure to mouse antibodies or prior VEGF or VEGF receptor targeted treatment or other anti-angiogenic-directed, anti-cancer treatment including thalidomide. * No prior consolidation therapy with cytotoxic agents for ovarian cancer. * Continuation of hormone replacement therapy is permitted. * No requirement for concomitant anticoagulant therapy. * Administration of low dose anticoagulants for maintenance of central venous access is permitted.No chronic oral or intravenous steroid use.